DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $266,973 | -57.2% | 12,941 | -38.8% | 0.07% | -56.1% |
| Q2 2023 | $623,546 | +54.8% | 21,130 | +20.9% | 0.16% | +43.5% |
| Q1 2023 | $402,716 | -5.6% | 17,479 | +14.0% | 0.11% | -6.9% |
| Q4 2022 | $426,550 | -9.4% | 15,338 | 0.0% | 0.12% | -10.1% |
| Q3 2022 | $471,000 | +29.0% | 15,338 | +23.5% | 0.13% | +41.8% |
| Q2 2022 | $365,000 | -8.5% | 12,416 | 0.0% | 0.09% | +8.3% |
| Q1 2022 | $399,000 | -28.0% | 12,416 | 0.0% | 0.08% | -18.4% |
| Q4 2021 | $554,000 | +45.4% | 12,416 | +64.5% | 0.10% | +33.8% |
| Q3 2021 | $381,000 | +42.7% | 7,547 | +121.4% | 0.08% | +48.1% |
| Q2 2021 | $267,000 | – | 3,408 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |